Clincosm LogoSign in Get a demo

Carcinoma, Hepatocellular

Showing NaN - NaN of 27
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CT Imaging for Guiding PA-TACE for HCC

Recruiting
  • Carcinoma, Hepatocellular
  • postoperative adjuvant transarterial chemoembolization
  • Guangzhou, Guangdong, China
    ZhuJiang Hospital of Southern Medical University
Nov 30, 2023

Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)

Recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +62 more
Feb 1, 2023

Carcinoma, Hepatocellular Trial in Worldwide (drug, biological, procedure)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Tucson, Arizona
  • +206 more
Jan 31, 2023

Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Tepotinib 300 mg
  • +4 more
  • Beijing, Beijing, China
  • +42 more
Aug 22, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +138 more
Aug 22, 2022

Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer Trial in China (Sitravatinib, Sitravatinib plus

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Gastric/Gastroesophageal Junction Cancer
  • Hefei, Anhui, China
  • +17 more
Jul 28, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)

Active, not recruiting
Has Results
  • Carcinoma, Hepatocellular
  • Phoenix, Arizona
  • +118 more
Jun 14, 2022

Carcinoma, Hepatocellular Trial in Worldwide (biological, drug, other)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +40 more
Mar 3, 2022

Carcinoma, Carcinoma, Hepatocellular, Liver Tumors Trial in Guangzhou (Hepatic arterial infusion chemo, Folfox Protocol,

Not yet recruiting
  • Carcinoma
  • +8 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Sep 22, 2021

Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))

Completed
  • Carcinoma, Hepatocellular
  • Refametinib (BAY86-9766)
  • Sorafenib (BAY43-9006)
  • Louisville, Kentucky
  • +78 more
Apr 6, 2021

Carcinoma, Hepatocellular, Liver Tumors, Sintilimab Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Sintilimab)

Unknown status
  • Carcinoma, Hepatocellular
  • +3 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Dec 20, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Regorafenib (Stivarga, BAY73-4506), Placebo)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Regorafenib (Stivarga, BAY73-4506)
  • Placebo
  • Los Angeles, California
  • +146 more
Aug 11, 2020

Prospective Surveillance for Very Early Hepatocellular Carcinoma

Recruiting
  • Carcinoma, Hepatocellular
    • Chongqing, Chongqing, China
    • +12 more
    May 20, 2020

    Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))

    Completed
    • Carcinoma, Hepatocellular
    • JNJ-42756493 (erdafitinib)
    • Changchun, China
    • +9 more
    Feb 17, 2020

    Carcinoma, Hepatocellular Trial in Guangzhou (pembrolizumab or nivolumab or JS001)

    Completed
    • Carcinoma, Hepatocellular
    • pembrolizumab or nivolumab or JS001
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Aug 16, 2019

    Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)

    Completed
    Has Results
    • Carcinoma, Hepatocellular
    • Sorafenib (Nexavar, BAY43-9006)
    • +2 more
    • San Francisco, California
    • +126 more
    May 16, 2019

    Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)

    Completed
    Has Results
    • Carcinoma, Hepatocellular
    • Nexavar (Sorafenib, BAY43-9006)
    • Placebo
    • Birmingham, Alabama
    • +198 more
    Jul 11, 2018

    Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)

    Completed
    Has Results
    • Carcinoma, Hepatocellular
    • Sorafenib (Nexavar, BAY43-9006)
    • Placebo
    • La Jolla, California
    • +106 more
    Jul 18, 2017

    Carcinoma, Hepatocellular Trial in Guangzhou (Adjuvant chemo, Follow-up)

    Unknown status
    • Carcinoma, Hepatocellular
    • Adjuvant chemotherapy
    • Follow-up
    • Guangzhou, Guangdong, China
      SUN YAT-SEN University Cancer Center
    Nov 1, 2016

    Carcinoma, Hepatocellular Trial in China, Taiwan, Thailand (Capecitabine, Peginterferon alfa-2a)

    Completed
    • Carcinoma, Hepatocellular
    • Beijing, China
    • +7 more
    Nov 1, 2016

    Carcinoma, Hepatocellular Trial in Guangzhou (Adjuvant TACE, Follow-up)

    Completed
    • Carcinoma, Hepatocellular
    • Adjuvant TACE
    • Follow-up
    • Guangzhou, Guangdong, China
      SUN YAT-SEN University Cancer Center
    Jun 16, 2016

    Carcinoma, Hepatocellular Trial in Guangzhou (Cytokine-Induced Killer Cells)

    Completed
    • Carcinoma, Hepatocellular
    • Cytokine-Induced Killer Cells
    • Guangzhou, Guangdong, China
      Immunotherapy
    Apr 13, 2016

    Carcinoma, Hepatocellular, Neoplastic Cells, Circulating Trial in China (TACE, Epirubicin, lipiodol)

    Unknown status
    • Carcinoma, Hepatocellular
    • Neoplastic Cells, Circulating
    • TACE
    • +2 more
    • Guangzhou, Guangdong, China
    • +5 more
    Dec 20, 2015

    Carcinoma, Hepatocellular Trial in Worldwide (Brivanib, Placebo)

    Terminated
    • Carcinoma, Hepatocellular
    • Hefei, Anhui, China
    • +31 more
    Sep 23, 2015

    Carcinoma, Hepatocellular Trial in China (TACE containing As2O3, TACE containing )

    Unknown status
    • Carcinoma, Hepatocellular
    • TACE containing As2O3
    • TACE containing placebo
    • Guangzhou, Guangdong, China
    • +4 more
    May 25, 2014